Media stories about Sophiris Bio (NASDAQ:SPHS) have been trending positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sophiris Bio earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.3577131860281 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Several brokerages have recently issued reports on SPHS. Maxim Group set a $6.00 price objective on Sophiris Bio and gave the stock a “buy” rating in a report on Monday, August 14th. HC Wainwright set a $6.00 price objective on Sophiris Bio and gave the stock a “buy” rating in a report on Friday, August 11th. Rodman & Renshaw reaffirmed a “buy” rating and set a $6.00 price objective on shares of Sophiris Bio in a report on Thursday, June 1st. Finally, ValuEngine cut Sophiris Bio from a “hold” rating to a “sell” rating in a report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Sophiris Bio has a consensus rating of “Buy” and a consensus price target of $6.60.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/sophiris-bio-sphs-given-daily-media-sentiment-score-of-0-26/1587722.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Insider Buying and Selling by Quarter for Sophiris Bio (NASDAQ:SPHS)

Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.